1. Li, S. Z. (1975) Materials medica principles: Describes 1,892 kinds of medical material in 1578 AD. pp. 145–168. In: Ben-Cao and Gang-mu (eds.). The Great Pharmacopoei. University of California Press, Beijing, P. R China.
2. Hajto, T., K. Hostanska, K. Frei, G. Rordorf, and H. J. Gabius (1990) Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res. 50: 3322–3326.
3. Friess, H., H. G. Beger, J. Kunz, N. Funk, M. Schilling, and M. W. Büchler (1996) Treatment of advanced pancreatic cancer with mistletoe: Results of a pilot trial. Anticancer Res. 16: 915–920.
4. Schultze, J. L., A. Stettin, and P. A. Berg, (1991) Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.). Klin. Wochenschr. 396: 261–265.
5. Park, W. B., S. Y. Lyu, J. H. Kim, S. H. Choi, H. K. Chung, S. H. Ahn, S. Y. Hong, T. J. Yoon, and M. J. Choi (2001) Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biother. Radiopharm. 16: 439–447.